Acute and sustained effects of isosorbide 5-mononitrate in stable angina pectoris

The American Journal of Cardiology
R S KohliE B Raftery

Abstract

Isosorbide 5-mononitrate (IS 5-MN) is an active metabolite of isosorbide dinitrate and is widely used as an antianginal agent. The acute and subacute (2 weeks) effects of IS 5-MN, 40 mg twice daily, were evaluated in 18 patients with stable angina pectoris using computerized exercise testing and a placebo-controlled, double-blind, randomized trial protocol. There were 2 phases of 2 weeks each in which patients received placebo or active IS 5-MN. Acute testing (8 patients) was performed 2 hours after the first dose and subacute testing 2 hours after the morning dose on day 14. Acute testing showed an increase in exercise time from a mean (+/- standard error of mean) of 8.2 +/- 0.6 minutes to 11.1 +/- 0.5 minutes (p less than 0.001) after a single dose of IS 5-MN. Time to 1 mm of ST depression increased significantly and peak exercise ST-segment depression decreased significantly. Rest and peak exercise heart rate increased significantly during acute testing with IS 5-MN; blood pressure did not change significantly. After 2 weeks of therapy, exercise time had not changed (9.9 +/- 0.6 with placebo to 9.7 +/- 0.6 minutes). The beneficial effects on ST-segment variables were sustained at 2 weeks. The data suggest that there is an at...Continue Reading

References

Jul 1, 1974·Journal of Pharmaceutical Sciences·W H DownR K Grundy
Jul 1, 1981·The American Journal of Medicine·W S ColucciE Braunwald
Mar 1, 1984·The American Journal of Cardiology·N S KhurmiE B Raftery
Aug 1, 1984·International Journal of Cardiology·N S KhurmiE B Raftery
Nov 1, 1983·Circulation·J O ParkerJ A Stone
Jan 1, 1980·American Heart Journal·J Abrams
Jun 27, 1983·The American Journal of Medicine·P W Armstrong, J A Moffat
Jan 1, 1981·European Journal of Clinical Pharmacology·U Abshagen, S Spörl-Radun
Oct 1, 1980·European Journal of Clinical Pharmacology·S Spörl-RadunU Abshagen

❮ Previous
Next ❯

Citations

Aug 1, 1994·Cardiovascular Drugs and Therapy·U Thadani, R J Lipicky
Nov 1, 2003·Current Therapeutic Research, Clinical and Experimental·Mickie PreisHaim Reuveni
Feb 19, 1998·The New England Journal of Medicine·J D Parker, J O Parker
Jun 19, 2010·International Journal of Cardiology·Jiafu WeiDejia Huang
Aug 11, 2006·Current Opinion in Cardiology·Ami B Bhatt, Peter H Stone
Oct 1, 1992·Alimentary Pharmacology & Therapeutics·R D Grose, P C Hayes
Jul 1, 1988·The Journal of International Medical Research·S I AnkierJ M Sneddon
Jan 1, 1993·The Journal of International Medical Research·P Löfdahl
Nov 1, 1987·Drug Intelligence & Clinical Pharmacy·F P Zeller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.